Reactions under sunlight and results Substrate Reagent/Catalyst Solvent Amount Rxn Concn
Phenytoin equivalent, mg/L (and cross-reactivity (a,b), %) TDx TDx-II Fosphenytoin concn
, ng/L Expected Measured by RIA (added) (mean [+ or -] SD) Calculated (a) Recovery, % Pool 1 0 <1 -- -- 25 <1 -- -- 100 10.
cutoff, mg/L (a) TPC Theophylline, 20 Phenytoin, 22 Positive predictive value (b) 0.
Rate, % Tacrolimus concn
in blood, [micro]g/L Rejection Toxicity 0-5 34 0 5-15 17 34 >15 5 54
2] Carboplatin Adults with refractory Plasma AUC tumors and renal dysfunction (n = 22) Plasma AUC Adults with refractory tumors (n = 23) Previously untreated Calculated plasma ovarian cancer AUC patients (n = 24) Women with Calculated course advanced ovarian 1 plasma AUC cancer (n = 224) Adults with untreated Observed AUC advanced urothelial for ultrafilterable cancer (n = 10) carboplatin Previously treated Cumulative AUCs patients with various after 1, 2, or 3 refractory tumors courses (n = 31) Cisplatin 40 adults with various Total plasma cancers given platinum concn
At various 7[alpha]-Bio-T concentrations and at the optimum antibody dilution, the ratios of %B (7[alpha]-Bio-T concn
>0) to %B (7[alpha]-Bio-T concn
= 0) are then calculated and plotted against the tracer concentration.